diflucan 150 mg cietās kapsulas
pfizer europe ma eeig, belgium - flukonazols - kapsula, cietā - 150 mg
diflucan 2 mg/ml šķīdums infūzijām
pfizer limited, united kingdom - flukonazols - Šķīdums infūzijām - 2 mg/ml
diflucan 150 mg cietās kapsulas
pfizer europe ma eeig, belgium - flukonazols - kapsula, cietā - 150 mg
diflucan 150 mg cietās kapsulas
vinci farma, spain - flukonazols - cietās kapsulas - 150 mg
diflucan 150 mg cietās kapsulas
pfizer s.a, belgium - flukonazols - kapsula, cietā - 150 mg
diflucan 150 mg cietās kapsulas
pfizer s.a, belgium - flukonazols - kapsula, cietā - 150 mg
diflucan 150 mg kapsulas
pfizer europe ma eeig, belgium - flukonazols - kapsula - 150 mg
diflucan 150 mg cietās kapsulas
pfizer nv/sa, belgium - flukonazols - kapsula, cietā - 150 mg
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiski līdzekļi - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiski līdzekļi - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.